Pfizer, BioNTech claim their Covid-19 vaccine 90 pc effective in Phase 3 trial

Pfizer Inc and BioNTech SE on Monday said that their Covid-19 vaccine candidate showed 90 per cent effectiveness in Phase 3 trials